Oral Semaglutide Gets FDA Approval — A Turning Point for GLP-1 Weight Loss Therapy

For years, the primary limitation of GLP-1 receptor agonists like semaglutide was their requirement for weekly subcutaneous injections — a hurdle that deterred a meaningful portion of eligible patients. That barrier has now been substantially lowered. The FDA approved oral semaglutide 25 mg under the brand name Wegovy Pill in early 2026, making it the first GLP-1 agonist available in tablet form for the treatment of obesity. Data from the OASIS 4 trial showed mean body weight reductions of 13.6% over the study period, with nearly 80% of participants achieving at least 5% weight loss compared to just 31% on placebo.

The approval comes as the broader GLP-1 landscape is experiencing explosive growth. High-dose injectable semaglutide 7.2 mg, studied in the STEP-UP trial program, is showing even more substantial results — an average 18.7% body weight reduction in patients without diabetes. Meanwhile, the small-molecule oral GLP-1 agonist orforglipron, which does not require the specialized absorption conditions of peptide-based oral semaglutide, demonstrated up to 11.2% weight loss at the 36 mg dose in a Phase 3 trial of over 3,000 patients at 72 weeks.

These developments collectively represent a maturation of the GLP-1 drug class from injectable specialty medication to potentially widespread oral therapy. Pfizer's ultra-long-acting injectable PF-08653944 is also advancing, having met its primary endpoint in Phase 2b with the potential for monthly dosing — a frequency that would further reduce treatment burden. Analysts project the oral GLP-1 space alone could reshape the obesity treatment market significantly over the next decade.